AFATINIB DIMALEATE
| Brand name | GILOTRIF |
|---|---|
| Active ingredient | AFATINIB DIMALEATE |
| Strength | EQ 20MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2013 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10004743*PED | January 2031 | — |
| 10004743 | July 2030 | product |
| 8545884*PED | June 2030 | — |
| 8426586*PED | April 2030 | — |
| 8545884 | December 2029 | product |
| 8426586 | October 2029 | substance |
| 9539258*PED | May 2027 | — |
| 9539258 | November 2026 | use U-1950 |
| RE43431*PED | July 2026 | — |
| RE43431 | January 2026 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.